Parameter
| Biomarker | CDKN2A | Full name | Cyclin-dependent kinase inhibitor 2A gene | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Macromolecule | Molecular Weight | / | Core Functional Dimensions | Prognosis, risk stratification |
| Disease | Pituitary Adenoma | Disease Subtypes | / | ||
| Organ | Pituitary | Test Sample / Technology Platform | Organization (methylation sequencing, IHC) | ||
| Pathobiological Mechanisms | Coding, p16 protein methylation result in cell cycle control | ||||
| Clinical Availability Status | Clinical application: 70% NFPA methylation, positively related to the tumor invasive, the recurrence rate | ||||
| Notes and Dynamics | It is a key indicator for screening high-risk NFPA | ||||